top
    Home
    Registration
    Accommodation
    Invitation Letter
    Contact Us
     Home
     Welcome Note
     Congress Chairpersons
     Scientific Committee
     Faculty
     Scientific Program
     Timetable
     CME
     Young Investigators Posters
         Submission Guidelines
         Poster Presentation Guidelines
         Award Ceremony
         Poster Texts
     Registration
         Invitation Letter
     Sponsors
     Sponsorship & Exhibition
     Accommodation
         Hotel Rey Juan Carlos
         Hotel Senator Barcelona
     General Information
         Before you travel...
         Transportation
         Italian Agent
         Tips and Hints
     About Barcelona
     Partners
  
1st World Congress on
Controversies in the Management of Viral Hepatitis (C-Hep)
Palau de Congressos de Catalunya, Barcelona, Spain, 19-22 May, 2011
 
  Scientific Program Print
 
 
Thursday, May 19, 2011

Opening Session
Hall A
17:30-18:30
Opening Session
17:30-17:35
Welcome Remarks
 
17:35-17:40
Moderator: Rafael Esteban, Spain
17:40-18:00
Honorary Opening Lecture: Who has Hepatitis C in 2011? Rafael Esteban, Spain
 
18:00-18:20
Hepatitis B: Any controversies left? Greg Dore, Australia
 
18:20-18:30
Discussion

18:30-20:00
Welcome Reception

Friday, May 20, 2011

Plenary Session 1
Hall A
08:30-10:00
Direct Antivirals: The Future is Now
08:30-08:35
Chairpersons Welcome Address
Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel
08:35-08:40
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem, Germany
 
HCV Direct Acting Antivirals:
08:40-08:45 Moderators: Stefan Zeuzem, Germany & Rafael Esteban, Spain
08:45-09:05
What are they? Christoph Sarrazin, Germany
09:05-09:25 Who needs them? David Nelson, USA
09:25-09:45 How to use them? Paul Kwo, USA
09:45-10:00 Discussion

10:00-10:30
Coffee Break

Plenary Session 2
Hall A
10:30-12:00
First Line Therapy: Are there preferred options?
10:30-10:35 Moderators: Stefan Zeuzem, Germany & Rafael Esteban, Spain
10:35-11:00
HCV Protease inhibitors: Overview of a new class of HCV drugs: Kenneth Sherman, USA
 
PEG-IFNα2a vs. PEG-IFNα2b vs. New Interferons
 
11:00-11:15
PEG-IFNα2a: Stefan Zeuzem, Germany
 
11:15-11:30
PEG-IFNα2b: Rafael Esteban, Spain
 
11:30-11:45 New Interferons: Douglas Dieterich, USA
 
11:45-12:00 Discussion

12:00-13:15
Janssen Satellite Symposium
Why DAAs will Make a Difference: A New HCV Treatment Era
12:00-12:05
Welcome and introduction
Xavier Forns, Spain
12:05-12:20
Why DAAs will make a difference: efficacy and safety in treatment-naïve patients with HCV
Xavier Forns, Spain
12:20-12:40
How will previously treated patients benefit in the new HCV treatment era?
Graham Foster, UK
12:40-12:55
How will drug-drug interactions with DAAs affect patient management?
David Back, UK
12:55-13:10
Does resistance matter? Understanding the mechanisms and implications
Christoph Sarrazin, Germany
13:10-13:15
Summary and key learnings
Xavier Forns, Spain
13:15
Meeting close

13:15-14:00
Lunch Break

Plenary Session 3
Hall A
14:00-15:00
Liver Biopsies: End of the Game?
14:00-14:05
Moderator: Charles Boucher, The Netherlands
 
14:05-14:25
New diagnostics for evaluating the liver, first line: Thierry Poynard, France
 
14:25-14:45
New diagnostics for evaluating the virus: Jean Michel Pawlotsky, France
14:45-15:00 Discussion

Session 4
Hall A
15:00-16:00
Is there still a need for liver biopsies?
15:00-15:05
Moderator: Ulrich Spengler, Germany
15:05-15:25
Yes: Kenneth Sherman, USA

15:25-15:45

No: Thierry Poynard, France

15:45-16:00 Discussion

Session 5
Hall B
15:00-16:00
Does drug resistance testing have a clinical role in HCV therapy?
15:00-15:05
Moderator: Jonathan Schapiro, Israel
 
15:05-15:25
Pro: Charles Boucher, The Netherlands
15:25-15:45
Con: Jean Michel Pawlotsky, France
15:45-16:00 Discussion

Session 6
Hall C
15:00-16:00
Frequent viral load monitoring: Necessity or Luxury?
15:00-15:05
Moderator: Stefan Mauss, Germany
15:05-15:25
Necessity: Vicente Soriano, Spain
 
15:25-15:45
Luxury: Hans Tillmann, USA
15:45-16:00
Discussion

16:00-16:15
Young Investigators Posters Award Ceremony
Sponsored by Roche

16:00-16:30
Coffee Break

Session 7A
Hall A
16:30-17:30
Clinical Cases: Treatment of Hepatitis C: Case 1
Raffaele Bruno, Italy

Session 7B
Hall B
16:30-17:30
Clinical Cases: Treatment of Hepatitis C: Case 2
Lars Peters, Denmark

Session 7C
Hall C
16:30-17:30
Clinical Cases: Treatment of Hepatitis C: Case 3
Xavier Forns, Spain

Saturday, May 21, 2011

Session 8
Hall A
09:00-10:00
HIV/HCV Co-infected Patients: Time to treat or time to wait?
09:00-09:05
Moderator: Marion Peters, USA
09:00-09:25
Treat: Stefan Mauss, Germany
09:25-09:45
Wait: Brian Gazzard, UK
09:45-10:00
Discussion

Session 9
Hall B
09:00-10:00
Incorporating genetic markers into routine clinical care: Now or Later?
 
09:00-09:05
Moderator: Hans Tillmann, USA

09:00-09:25
Now: Andri Rauch, Switzerland
 
09:25-09:45
Later: Ulrich Spengler, Germany
09:45-10:00
Discussion

Session 10
Hall C
09:00-10:00
Acute Hepatitis C: What is new?
09:00-09:15 Introduction and Moderator: Jürgen Rockstroh, Germany
09:15-09:30 Do we need ribavirin for treatment of acute hepatitis C in HIV co-infected patients?

09:30-09:45
Yes: Mark Nelson, UK

09:30-09:45
No: Martin Vogel, Germany

09:45-10:00
Discussion

10:00-10:30
Coffee Break

Plenary Session 11
Hall A
10:30-12:00
HBV Therapy in 2011
10:30-10:35
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France
 
10:35-10:40
Moderators: Fabien Zoulim, France & Maria Buti, Spain
10:40-11:00 Hepatitis B therapy: Pietro Lampertico, Italy
11:00-11:15
Is Hepatitis B curable? Fabien Zoulim, France
 
Interferon or oral anti-HBV drugs for first line therapy?
11:15-11:30 Interferon: Patrick Marcellin, France

11:30-11:45
Oral anti-HBV drugs: Maria Buti, Spain
11:45-12:00 Discussion

12:00-13:15
MSD Sponsored Satellite Symposium
Unlocking new possibilities in the treatment of HCV G1:
The Future of Direct Acting Antivirals
Chairman: Rafael Esteban-Mur
, Spain
12:00-12:05
Opening Remarks
Rafael Esteban Mur, Spain
12:05-12:25
Emerging Clinical Data with New Direct Acting Antivirals
Rafael Esteban Mur, Spain
12:25-12:45
Early predictors of response with new New Direct Acting Antivirals
Jean Michel Pawlotsky, France
12:45-12:55
Optimizing Side Effect Management with New Direct Acting Antivirals
Michael Manns, Germany
12:55-13:10
Panel Discussion – Q&A
13:10-13:15
Closing Remarks
Rafael Esteban Mur, Spain

13:15-14:00
Lunch Break

Plenary Session 12
Hall A
14:00-15:00
Clinical Cases: Hepatitis B
Supported by an unrestricted grant from Gilead Sciences
    
14:00-14:05
Moderator: Fabien Zoulim, France

14:05-14:20
Thomas Berg, Germany

14:20-14:35 Maria Buti, Spain

14:35-14:50 Geoffrey Dusheiko, UK
14:50-16:00 Discussion

Plenary Session 13
Hall A
15:00-16:00
Hot Topics in Viral Hepatitis
15:00-15:05
Moderator: Douglas Dieterich, USA & Massimo Puoti, Italy

15:05-15:20
Treatment of hepatitis Delta: Heiner Wedemeyer, Germany

15:20-15:35
Silibinin rescue therapy: Thomas Berg, Germany
15:35-16:00
Discussion

16:00-16:30
Coffee Break

16:30-17:30
"Pipeline Showcase"
Moderator: Jonathan Schapiro, Israel
16:30-16:45
IDX184 and IDX375: Novel HCV Polymerase Inhibitors
Douglas L. Mayers, USA (Presentation supported by Idenix)
16:45-17:00
Second generation Protease Inhibitor BI201335: promising clinical results in chronic
Hepatitis C
Tarik Asselah, France (Presentation supported by Boehringer Ingelheim)
17:00-17:15
Hepatitis C: Drugs in Development at Abbott Laboratories
Barry Bernstein, USA (Presentation supported by Abbott)
17:15-17:30
Potent Nucleotide Analogs in HCV: High Barrier to Resistance and Broad Genotype Activity
Patrick Marcellin, France (Presentation supported by Pharmasset)

Sunday, May 22, 2011

Plenary Session 14
Hall A
09:00-10:00
Management of ESLD
09:00-09:05
Moderators: Heiner Wedemeyer, Germany & Geoffrey Dusheiko, UK
09:05-09:25
Liver Transplantation in 2011: Marion Peters, USA

09:25-09:45
Portal hypertension: State of the art: Ulrich Spengler, Germany

09:45-10:00 Discussion

10:00-10:30
Coffee Break

Plenary Session 15
Hall A
10:30-12:00
Beyond the Horizon
 
10:30-10:35
Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel
 
Can HCV be cured without interferon?
10:35-10:55 Yes: Heiner Wedemeyer, Germany
10:55-11:15 No: Geoffrey Dusheiko, UK
11:15-11:30
Discussion
 
11:30-11:50
The Future is Now: Michael Manns, Germany
11:50-12:00
Congress Chairpersons closure and summary
Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 10/16/2011 Created by     WebStudio.co.il